Stay updated with breaking news from Long Term Extension Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating...
Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only...
New analyses, including late-breaking data and presentations on CAMZYOS® and Eliquis® , reaffirm the company's steadfast dedication to tackling cardiovascular diseases ...
Over 2 years of treatment with tolebrutinib was safe and kept relapse rates low for multiple sclerosis patients in a Phase 2 trial extension.
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and...